GF
NBIX icon

Gries Financial’s Neurocrine Biosciences NBIX Stock Holding History

Gries Financial’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,626
Closed -$222K – 298
2024
Q4 		$222K Buy
+1,626
New +$201K 0.04% 251
2024
Q3 		– Sell
-1,933
Closed -$266K – 279
2024
Q2 		$266K Sell
1,933
-39
-2% -$5.35K 0.05% 204
2024
Q1 		$272K Buy
1,972
+102
+5% +$13.9K 0.05% 229
2023
Q4 		$246K Buy
+1,870
New +$215K 0.05% 185

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Gries Financial's NBIX Position: Q1 2025 in Review

Gries Financial sold out of Neurocrine Biosciences (NBIX) in Q1 2025, closing a stake of 1,626 shares — an estimated $222K sold.

Gries Financial first reported a position in NBIX in Q4 2023 and held it in 4 quarters. The position peaked at $272K in Q1 2024. 586 funds tracked by Wall St. Rank hold NBIX as of Q1 2025.

  • Gries Financial reported no remaining Neurocrine Biosciences position as of Q1 2025 after selling out during the quarter.
  • Gries Financial sold 1,626 Neurocrine Biosciences shares in Q1 2025, an estimated $222K.
  • Gries Financial first reported a position in Neurocrine Biosciences in Q4 2023 and held it in 4 quarters.
  • Gries Financial's Neurocrine Biosciences position peaked at $272K in Q1 2024.
  • 586 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2025.

Based on Gries Financial's 13F filing for Q1 2025, filed 5 May 2025.